J&J to spend $200 million to speed Ebola vaccine

Share

Johnson & Johnson has decided to spend up to $200 million to accelerate the production of its Ebola vaccine program. J&J and the National Institutes of Health have developed a combination vaccine with Denmark’s Bavarian Nordic, which shows promising results in preclinical studies. The plan is to now test for safety and immunogenicity in healthy volunteers in Europe, the USA and Africa. The start date is scheduled for January 2015. This ramp up to get an Ebola vaccine as quickly as possible to the public has become a race among several firms as well as countries. The ultimate goal of the race is to save lives and protect those people most at risk of being infected by this deadly disease.

Read more at PharmaTimes…

Share

Comments are closed.